Mouse Models for Atherosclerosis Research—Which Is My Line?
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Atherosclerosis is one of the primary causes of cardiovascular disease and mortality. This chronic immunometabolic disease evolves during decades in humans and encompasses different organs and immune cell types, as well as local and systemic processes that promote the progression of the disease. The most frequently used animal model to study these atherogenic processes and inter-organ crosstalk in a short time frame are genetically modified mouse models. Some models have been used throughout the last decades, and some others been developed recently. These models have important differences in cholesterol and lipoprotein metabolism, reverse cholesterol transport pathway, obesity and diabetes as well as inflammatory processes. Therefore, the disease develops and progresses differently in the various mouse models. Since atherosclerosis is a multifaceted disease and many processes contribute to its progression, the choice of the right mouse model is important to study specific aspects of the disease. We will describe the different mouse models and provide a roadmap to facilitate current and future atherosclerosis researchers to choose the right model depending on their scientific question.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237
ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.
Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L., & Ross, R. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.1.133 · Cited by 1,693 · cited 2×
“Apoe knockout mice show a significant increase of total plasma cholesterol compared to wild-type mice under chow diet: 400–600 and 75–110 mg/dl, respectively (23).”
BackgroundCholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport
Rosenson, R. S., Brewer, H. B., Davidson, W. S., Fayad, Z. A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X.-C., Phillips, M. C., Rader, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.066589 · Cited by 953
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“Although the use of AAVs seems to be pretty save and without pathogenicity, one might still consider a possible anti-viral host immune response of the organism (56).”
BackgroundApolipoprotein E: from cardiovascular disease to neurodegenerative disorders
Mahley, R. W. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1427-y · Cited by 837
Scavenger Receptors in Atherosclerosis: Beyond Lipid Uptake
Moore, K. J., & Freeman, M. W. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000229218.97976.43 · Cited by 562
Animal models of atherosclerosis
Emini Veseli, B., Perrotta, P., De Meyer, G. R. A., Roth, L., Van der Donckt, C., Martinet, W., & De Meyer, G. R. Y. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.010 · Cited by 548
The role of non-resolving inflammation in atherosclerosis
Kasikara, C., Doran, A. C., Cai, B., & Tabas, I. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97950 · Cited by 266 · cited 1×
“Efferocytosis, the phagocytic clearance of dead cells and cellular debris, plays important functions in the resolution of inflammation and is mainly mediated by macrophages and other immune phagocytes (54).”
BackgroundXu, Y., Li, F., Zalzala, M., Xu, J., Gonzalez, F. J., Adorini, L., Lee, Y., Yin, L., & Zhang, Y. (2016) · Hepatology · doi:10.1002/hep.28712 · Cited by 172 · cited 1×
“glycin conjugation) and increased synthesis of bile acids is another reason for an improved reverse cholesterol transport and fecal cholesterol excretion in mice (11).”
BackgroundIdentification and characterization of LRP8 (apoER2) in human blood platelets
Riddell, D. R., Vinogradov, D. V., Stannard, A. K., Chadwick, N., & Owen, J. S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34910-5 · Cited by 106
Role of the Cytokine-like Hormone Leptin in Muscle-bone Crosstalk with Aging
Hamrick, M. W. (2017) · Journal of Bone Metabolism · doi:10.11005/jbm.2017.24.1.1 · Cited by 77 · cited 1×
“Therefore, deficiency of leptin or the leptin receptor leads an impaired energy expenditure and increased food intake, and thus to obesity (44, 45).”
Background
Cited by
Mattioli, R., Francioso, A., Mosca, L., & Silva, P. (2020) · Molecules · doi:10.3390/molecules25173809 · Cited by 1,042
Neutrophils in chronic inflammatory diseases
Herrero-Cervera, A., Soehnlein, O., & Kenne, E. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00832-3 · Cited by 695
Tung, M.-C., Lan, Y.-W., Li, H.-H., Chen, H.-L., Chen, S.-Y., Chen, Y.-H., Lin, C.-C., Tu, M.-Y., & Chen, C.-M. (2020) · Scientific Reports · doi:10.1038/s41598-020-65782-8 · Cited by 57
Metadata
- Authors
- Oppi, S., Lüscher, T. F., & Stein, S.
- Venue
- Frontiers in Cardiovascular Medicine
- Publisher
- Frontiers Media SA
- Published
- 2019-04-12
- Volume
- 6
- Pages
- 46-46
- ISSN
- 2297-055X (ISSN-L)
- OpenAlex
- W2938688210
- Cited by
- 178
- References
- 13
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.